Research-based, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic agents to treat serious unmet medical needs. Based in San Francisco, CA, FibroGen scheduled a $124 million IPO on Nasdaq with a market capitalization of $975 million at a price range midpoint of $17.50 for Friday, Nov. 14, 2014.
http://ift.tt/1EF5HoE
http://ift.tt/1EF5HoE
No comments:
Post a Comment